- 专利标题: FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF
-
申请号: US16042271申请日: 2018-07-23
-
公开(公告)号: US20190177271A1公开(公告)日: 2019-06-13
- 发明人: Takahisa MOTOMURA , Hironobu NAGAMORI , Koichi SUZAWA , Hirotsugu ITO , Toru MORITA , Satoru KOBAYASHI , Hisashi SHINKAI
- 申请人: JAPAN TOBACCO INC.
- 优先权: JP2008-264681 20081010; JP2009-209855 20090910
- 主分类号: C07D205/04
- IPC分类号: C07D205/04 ; C07F7/08 ; C07D295/192 ; C07D207/04 ; C07D211/06 ; C07D213/30 ; C07D213/56 ; C07D403/12 ; C07D401/12 ; C07D401/06 ; C07D333/22 ; C07D295/18 ; C07D295/08 ; C07D275/02 ; C07D271/10 ; C07D271/06 ; C07D263/32 ; C07D257/04 ; C07D249/08 ; C07D239/26 ; C07D231/12 ; C07C317/22 ; C07C311/04 ; C07C271/30 ; C07C271/16 ; C07C259/10 ; C07C255/53 ; C07C255/12 ; C07C235/66 ; C07C235/42 ; C07C233/25 ; C07C233/18 ; C07C217/20 ; C07C215/70 ; C07C215/44 ; C07C69/76 ; C07C69/732 ; C07C69/712 ; C07C65/17 ; C07C59/72 ; C07C59/56 ; C07C49/83 ; C07C43/253 ; C07C43/23 ; C07C39/42 ; C07C35/52 ; A61K31/5375 ; A61K31/4523 ; A61K31/4453 ; A61K31/4439 ; A61K31/4409 ; A61K31/4406 ; A61K31/4402 ; A61K31/44 ; A61K31/435 ; A61K31/425 ; A61K31/4245 ; A61K31/421 ; A61K31/4196 ; A61K31/4155 ; A61K31/415 ; A61K31/41 ; A61K31/401 ; A61K31/40 ; A61K31/397 ; A61K31/381 ; A61K31/277 ; A61K31/235 ; A61K31/192 ; A61K31/167 ; A61K31/166 ; A61K31/136 ; A61K31/121 ; A61K31/10 ; A61K31/085 ; A61K31/05 ; A61K31/045
摘要:
The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.
信息查询